# US 2022/0034854 A1 · Diagnosis of tuberculosis and other diseases using exhaled breath

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034854 A1
- Document ID: US20220034854A1
- Status: Published application
- Kind: A1
- Application number: 17/499,848
- Filed: 2021-10-12
- Published: 2022-02-03
- Earliest claimed: 2019-08-26
- Assignees: Zeteo Tech, Inc.
- Applicants: Zeteo Tech, Inc.
- Inventors: Dapeng Chen; Wayne A. Bryden; Michael McLoughlin
- Web page: https://patentgrep.com/patent/US20220034854A1

## CPC

- G01N 30/7206: {interfaced to gas chromatograph (interfaces in general for introducing or extracting samples to be analysed with specially adapted mass spectrometer, see H01J49/04)}
- A61B 5/082: {Evaluation by breath analysis, e.g. determination of the chemical composition of exhaled breath (A61B5/083, A61B5/091 take precedence)}
- A61B 5/091: Measuring volume of inspired or expired gases, e.g. to determine lung capacity
- A61B 5/097: Devices for facilitating collection of breath or for directing breath into or through measuring devices
- A61B 10/00: Instruments for taking body samples for diagnostic purposes (for taking samples of blood A61B5/15); Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B 10/0045: {Devices for taking samples of body liquids}
- G01N 33/497: of gaseous biological material, e.g. breath
- A61B 5/0833: {Measuring rate of oxygen consumption}
- A61B 5/0836: {Measuring rate of CO2 production}
- A61B 5/087: Measuring breath flow
- A61B 2010/0087: {Breath samples}
- A61B 2562/029: Humidity sensors
- G01N 2030/025: {Gas chromatography}
- G01N 2800/12: Pulmonary diseases
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Disclosed are methods and devices for analyzing aerosol particles in exhaled breath using diagnostic tools that enable rapid, low cost and autonomous point of care assays for several diseases including respiratory tract diseases. Disclosed are methods and devices for capturing exhaled breath aerosols in a packed bed column and analyzing exhaled captured breath aerosols for tuberculosis diagnosis.

## Claims

### Claim 1

A system for diagnosing respiratory diseases in an individual using exhaled breath, the system comprising:
a sample collection system comprising:
a sample extraction component configured to receive an individual's face for extracting breath aerosol (EBA) particles expelled from the individual during a predetermined number of breath maneuvers into a flow of air fed into the extraction component;
a sample capture component comprising:
means to collect the EBA particles into a collected liquid sample; and,
a packed bed column to selectively capture the EBA particles from the collected liquid sample onto the packed bed;
means to elute the collected EBA particles from the packed bed using one or more solvents; and,
a diagnostic device for analyzing the EBA particles comprised in the one or more solvents.

### Claim 2 (depends on 1)

The system of claim 1 wherein the EBA particles comprises at least one of microbes, virus, metabolite biomarkers, lipid biomarkers, and proteomic biomarkers characteristic of the respiratory disease.

### Claim 3 (depends on 1)

The system of claim 1 wherein the flow rate of air entering the sample capture component is between about 50 L/min and about 500 L/min.

### Claim 4 (depends on 1)

The system of claim 1 wherein the volume of the collected sample is between about 100 microliter and about 10 ml.

### Claim 5 (depends on 1)

The system of claim 1 wherein the means to collect the EBA particles comprises an air pump and an impactor wherein the air pump provides the flow of air to carry the exhaled breath from the extraction component into the impactor and wherein the impactor separates the EBA particles from exhaled breath to produce the collected sample.

### Claim 6 (depends on 5)

The system of claim 5 wherein the impactor comprises at least one of a cyclone, a wetted wall cyclone, one or more wetted film impactors, a virtual impactor, and an impinger.

### Claim 7 (depends on 1)

The system of claim 1 wherein the sample extraction component comprises at least one of a cone shaped device, a shroud, CPR rescue mask, a CPAP mask, a ventilator mask, and a medical universal mouthpiece.

### Claim 8 (depends on 1)

The system of claim 1 wherein the diagnostic device comprises at least one of PCR, rt-PCR, immuno-based assay, mass spectrometer (MS), MALDI-MS, ESI-MS, GC-MS, GC-IMS and MALDI-TOFMS.

### Claim 9 (depends on 1)

The system of claim 1 further comprising one or more chilling devices configured to be in thermal communication with the means to collect the EBA particles.

### Claim 10 (depends on 9)

The system of claim 9 wherein the means to collect the EBA particles is chilled to a temperature greater than about 0° C. and less than about 10° C. using the one or more chilling devices.

### Claim 11 (depends on 9)

The system of claim 9 wherein the means to collect the EBA particles is chilled to a temperature greater than about 0° C. and less than about 4° C. using the one or more chilling devices.

### Claim 12 (depends on 1)

The system of claim 1 further comprising one or more sensors configured be in fluid communication with the sample extraction component wherein the output of the one or more sensors is used to calculate the total cumulative volume of exhaled breath aerosol particles entering the sample capture component.

### Claim 13 (depends on 12)

The system of claim 12 wherein the one or more sensors comprises at least one of a CO2 sensor, an oxygen sensor, a humidity sensor, an optical particle size counter, an aerodynamic particle sizer, and a nephelometer.

### Claim 14 (depends on 1)

The system of claim 1 wherein the collected sample is transferred to the packed bed column using at least one of a dispensing pump and a robotic sample transfer system.

### Claim 15 (depends on 2)

The system of claim 2 wherein the lipid biomarkers comprise biomarkers characteristic of Mtb.

### Claim 16 (depends on 1)

The system of claim 1 wherein the packed bed column comprises solid particles comprising at least one of resins, cellulose, silica, agarose, and hydrated Fe3O4 nanoparticles.

### Claim 17 (depends on 1)

The system of claim 1 wherein the packed bed column comprises resin beads having C18 functional groups on the surface.

### Claim 18 (depends on 17)

The system of claim 17 wherein the resin beads have a nominal diameter of between about 12 μm and about 20 μm.

### Claim 19 (depends on 17)

The system of claim 17 wherein the weight of the packed bed is about 25 mg.

### Claim 20 (depends on 1)

The system of claim 1 wherein the means to elute the collected EBA particles from the packed bed comprises at least one of one or more syringes, and one or more pumps.

### Claim 21 (depends on 1)

The system of claim 1 wherein the solvent comprises at least one of acetonitrile, methanol, acid, isopropanol, the remaining being water.

### Claim 22

A method for diagnosing respiratory diseases in an individual using exhaled breath, the method comprising:
extracting EBA particles expelled into a flow of air fed into a sample extraction component configured to receive an individual's face;
collecting the EBA particles from exhaled breath and air as a collected liquid sample;
capturing the EBA particles in the collected liquid sample using a packed bed column to selectively capture the EBA particles from the collected liquid sample onto the packed bed; and,
eluting the collected EBA particles from the packed bed using one or more solvents; and,
analyzing the EBA particles comprised in the one or more solvents.

### Claim 23 (depends on 22)

The method of claim 22 wherein the one or more solvents comprises at least one of acetonitrile, methanol, acid, isopropanol, the remaining being water.

### Claim 24 (depends on 22)

The method of claim 22 wherein the one or more solvents comprises between about 50 vol.-% and about 70 vol.-% acetonitrile in water.

### Claim 25 (depends on 22)

The method of claim 22 wherein the one or more solvents comprises between about 50 vol.-% and about 70 vol.-% isopropanol in water.

### Claim 26 (depends on 22)

The method of claim 22 wherein the eluting step comprises washing the packed bed column with about 50 vol.-% ACN in a first step and with about 70 vol.-% IPA in a second step.

### Claim 27 (depends on 22)

The method of claim 22 wherein the analysis step further comprises detecting at least one of lipid biomarkers PS 24:4, PI 18:4, Cer 8:0, DG O-8:0, and PI 20:4 to determine the presence or absence of tuberculosis.
